Keyphrases
Irinotecan
100%
Drug-eluting Beads
100%
DEBIRI
100%
Hepatic Colorectal Metastases
100%
Prescribed Dose
60%
Overall Survival
40%
Resection
20%
Progression-free Survival
20%
Abdominal Pain
20%
Consecutive Patients
20%
Total Bilirubin
20%
Kaplan-Meier
20%
Institutional Review Board
20%
Dose Delivery
20%
Multi-institutional
20%
Tumor Association
20%
Carcinoembryonic Antigen Levels
20%
Objective Response
20%
Response Evaluation Criteria in Solid Tumors (RECIST)
20%
Disease Control Rate
20%
Objective Response Rate
20%
Metastatic Colorectal Cancer (mCRC)
20%
Colorectal Liver Metastases
20%
Institutional Registry
20%
Stasis
20%
Modified Response Evaluation Criteria in Solid Tumors (mRECIST)
20%
European Association for the Study of the Liver
20%
Pharmacology, Toxicology and Pharmaceutical Science
Irinotecan
100%
Overall Survival
50%
Solid Malignant Neoplasm
50%
Metastatic Colorectal Cancer
50%
Diseases
50%
Progression Free Survival
25%
Abdominal Pain
25%
Bilirubin
25%
Carcinoembryonic Antigen
25%